Source disclosure: March 02, 2026, 13:00 JST
Published by Pulse News Wire: March 02, 2026, 13:50 JST
Chiome Bioscience Inc. [4583.T]
TOKYO, Mar 02 (Pulse News Wire) – Chiome Bioscience Inc. (4583.T) reported the exercise status of its 23rd tranche subscription rights (with adjustment clause) for February 2026.
A total of 1,436,200 shares were delivered during the month, representing 10.56% of the total issuance. As of the end of February, there were 10,773,800 shares remaining unexercised out of an initial 12,210,000 shares available. Additionally, the company announced the early redemption of its second series of unsubordinated corporate bonds issued on December 15, 2025, which was completed by the end of February 2026.
Detailed exercise activities for February included deliveries on various dates ranging from February 2 to February 27, with exercise prices varying between ¥101.2 and ¥105.8 per share. The highest delivery occurred on February 19, with 600,000 shares exercised. Chiome Bioscience also confirmed adherence to exercise limitations set forth by the Tokyo Stock Exchange's Listing Regulations Article 434 and the Japan Securities Dealers Association’s Rules Governing the Handling of Third-Party Allotments.
The overall exercise rate stood at 2.12%, well within regulatory limits.
AI-translated content. 🟢 Confidence: High See terms • Original filing